US transparency proposals may hurt drug firms, industry warns
This article was originally published in Scrip
The biopharmaceutical industry has expressed concern over draft proposals from the US FDA suggesting the agency discloses to the public information on drugs and biologics that have not yet been approved.
You may also be interested in...
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.